title: Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
abstract: Drug associated thrombotic microangiopathy (TMA) is a rare event causing thrombocytopenia, microangiopathic anemia, renal failure, and neurologic abnormalities. Here, we present a case of TMA that occurred during the first cycle of treatment with carfilzomib for relapsed multiple myeloma.
authors.affiliation: Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.|Department of Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Sullivan
authors.affiliation: Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.|Department of Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Alexey V
authors.initials: AV
authors.lastname: Danilov
authors.affiliation: Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.|Department of Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Frederick
authors.initials: F
authors.lastname: Lansigan
authors.affiliation: Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.|Department of Pathology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Dunbar
mesh_terms: D051722:ADAM Proteins / Q000172:deficiency; D000071120:ADAMTS13 Protein; D000368:Aged; D003221:Confusion / Q000139:chemically induced; D003937:Diagnosis, Differential; D003951:Diagnostic Errors; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D010951:Plasma Exchange; D061988:Proteasome Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D057049:Thrombotic Microangiopathies / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy*; D015275:Tumor Lysis Syndrome / Q000175:diagnosis; D014552:Urinary Tract Infections / Q000175:diagnosis
chemical_list: D009842:Oligopeptides; D061988:Proteasome Inhibitors; C524865:carfilzomib; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human
keywords: carfilzomib; multiple myeloma; plasma exchange; thrombotic microangiopathy